# A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain

> **NCT00410878** · PHASE1 · COMPLETED · sponsor: **Alza Corporation, DE, USA** · enrollment: 22 (actual)

## Conditions studied

- Pain
- Analgesics, Opioid

## Interventions

- **DRUG:** OROS Hydromorphone HCI (slow release)

## Key facts

- **NCT ID:** NCT00410878
- **Lead sponsor:** Alza Corporation, DE, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 1999-08
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410878, "A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00410878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*